Nano cap Plus Therapeutics (NASDAQ:PSTV) jumps 24% premarket on robust volume in reaction to U.S. Orphan Drug status for lead drug Rhenium NanoLiposomes (RNL) for the treatment of recurrent glioblastoma, an aggressive type of cancer of the brain or spinal cord.
RNL, designed to deliver a very high dose of radiation (up to 25x more than external beam radiation therapy) directly into the brain tumor, is currently being tested in a Phase 1 dose-finding study called ReSPECT.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.